PMC:7324763 / 55943-56298 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T899","span":{"begin":200,"end":207},"obj":"UBERON:0000479"},{"id":"T96654","span":{"begin":200,"end":207},"obj":"UBERON:0000479"}],"text":"Despite our best efforts in timing type I IFN therapy to mitigate immunopathology, these treatments still increase the risk of excessive activation of proinflammatory signals, which could damage host tissues and perpetuate immunopathology (180, 181). For this reason, alternative therapeutic avenues to direct type I IFN administration are being explored."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T703","span":{"begin":200,"end":207},"obj":"Body_part"}],"attributes":[{"id":"A703","pred":"fma_id","subj":"T703","obj":"http://purl.org/sig/ont/fma/fma9637"}],"text":"Despite our best efforts in timing type I IFN therapy to mitigate immunopathology, these treatments still increase the risk of excessive activation of proinflammatory signals, which could damage host tissues and perpetuate immunopathology (180, 181). For this reason, alternative therapeutic avenues to direct type I IFN administration are being explored."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T718","span":{"begin":137,"end":147},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T719","span":{"begin":167,"end":174},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T720","span":{"begin":245,"end":248},"obj":"http://purl.obolibrary.org/obo/CLO_0054057"}],"text":"Despite our best efforts in timing type I IFN therapy to mitigate immunopathology, these treatments still increase the risk of excessive activation of proinflammatory signals, which could damage host tissues and perpetuate immunopathology (180, 181). For this reason, alternative therapeutic avenues to direct type I IFN administration are being explored."}

{"project":"MyTest","denotations":[{"id":"32655581-26812607-34771768","span":{"begin":240,"end":243},"obj":"26812607"},{"id":"32655581-32527928-34771769","span":{"begin":245,"end":248},"obj":"32527928"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Despite our best efforts in timing type I IFN therapy to mitigate immunopathology, these treatments still increase the risk of excessive activation of proinflammatory signals, which could damage host tissues and perpetuate immunopathology (180, 181). For this reason, alternative therapeutic avenues to direct type I IFN administration are being explored."}

{"project":"TEST0","denotations":[{"id":"32655581-232-239-3171341","span":{"begin":240,"end":243},"obj":"[\"26812607\"]"},{"id":"32655581-233-240-3171342","span":{"begin":245,"end":248},"obj":"[\"32527928\"]"}],"text":"Despite our best efforts in timing type I IFN therapy to mitigate immunopathology, these treatments still increase the risk of excessive activation of proinflammatory signals, which could damage host tissues and perpetuate immunopathology (180, 181). For this reason, alternative therapeutic avenues to direct type I IFN administration are being explored."}

{"project":"2_test","denotations":[{"id":"32655581-26812607-34771768","span":{"begin":240,"end":243},"obj":"26812607"},{"id":"32655581-32527928-34771769","span":{"begin":245,"end":248},"obj":"32527928"}],"text":"Despite our best efforts in timing type I IFN therapy to mitigate immunopathology, these treatments still increase the risk of excessive activation of proinflammatory signals, which could damage host tissues and perpetuate immunopathology (180, 181). For this reason, alternative therapeutic avenues to direct type I IFN administration are being explored."}

{"project":"LitCovid-sentences","denotations":[{"id":"T343","span":{"begin":0,"end":250},"obj":"Sentence"},{"id":"T344","span":{"begin":251,"end":355},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Despite our best efforts in timing type I IFN therapy to mitigate immunopathology, these treatments still increase the risk of excessive activation of proinflammatory signals, which could damage host tissues and perpetuate immunopathology (180, 181). For this reason, alternative therapeutic avenues to direct type I IFN administration are being explored."}